Business
Cipher Pharmaceuticals completes distribution and supply agreement for isotretinoin product in Chile
Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON , June 18, 2014 /CNW/ - Cipher ...
About this update from Cipher Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\nToronto Stock Exchange Symbol: DND\n\n\nMISSISSAUGA, ON, June 18, 2014 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:\n DND) today announced it has entered into a definitive distribution and\n supply agreement with Laboratorios Andrómaco S.A. (\"Andrómaco\") under\n which Cipher has granted Andrómaco the exclusive right to market, sell\n and distribute Cipher's isotretinoin capsules in Chile.\n\n\nWith over 70 years of experience, Andrómaco is a leader in the\n production and marketing of pharmaceutical products in Chile and\n certain other Latin American countries. Once regulatory approval is\n granted, it is expected that Cipher's product will be marketed under\n the brand name Lisacne-CIP, replacing Andrómaco's current isotretinoin\n product, Lisacne. The branded dermatology products currently marketed\n by Andrómaco in Chile include Fucidin® and Daivonex®. Andrómaco is majority owned by Grünenthal GmbH, Germany.\n\n\n\"Extending the reach of our isotretinoin product is one of our growth\n priorities, and we believe Andrómaco is an excellent partner to bring\n this product to market in Chile,\" Larry Andrews, President and Chief\n Executive Officer of Cipher Pharmaceuticals.\n\n\nCipher's isotretinoin product is a patent-protected formulation of\n isotretinoin, which is used in the treatment of severe recalcitrant\n nodular acne. Isotretinoin is the most effective severe acne therapy\n available to teenagers who suffer from acne. The product is marketed in\n the United States as Absorica™ and in Canada as Epuris®.\n\n\nUnder the terms of the agreement, Cipher will supply product to\n Andrómaco. Product manufacturing will be fulfilled by Cipher's\n partner, Galephar Pharmaceutical Research.\n\n\nAbout Cipher Pharmaceuticals Inc.\n\n\nCipher Pharmaceuticals (TSX: DND) is a growing specialty pharmaceutical\n company with three commercial products and a fourth in development. Our\n product candidates are typically improved formulations of successful,\n currently marketed drugs. We in-license a product, manage the required\n clinical development and regulatory approval process, and either\n out-license it to a marketing partner, or, in Canada, we may market the\n product ourselves. Our core capabilities are in clinical and regulatory\...